CTTH — what changed in the latest 10-Q
A section-by-section comparison of CTTH's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2015-11-23 vs the prior 10-Q · 2015-08-19
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −20 | ~1 | 3 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 4 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 3 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2015-11-23
Our wholly owned subsidiary CTT Pharmaceutical Holdings (“CTT”) specializes in drug delivery systems technology within the pharmaceutical industry. CTT Pharma’s focus is fast dissolving drug delivery systems. The company’s revolutionary technology platform includes the development of advanced oral d…
The wafer is an orally administrable paper-thin polymer films used as a carrier for pharmaceutical agents. The wafer rapidly dissolves to release the pharmaceutical agent as soon as it comes in contact with saliva, thus obviating the need for water during administration. This attribute makes the waf…
For the three and nine months ended September 30, 2015 and 2014
For the three months and nine months ended September 30, 2015, we incurred a Net Loss of $(290,864) and $(990,572). This compares with a Net Loss of $(43,196) and $(11,424) for the comparable periods in 2014. The primary reason for the significant increase in our operating losses from 2014 to $2015 …
Foreign currency translations for all periods covered by this report were nominal.
Text removed vs the prior filing · source: 10-Q · 2015-08-19
CTT Pharmaceutical Holdings, Inc. (“CTT Pharmaceutical” or "the Company"), a Delaware Corporation, was incorporated on November 6, 1996 under the name Winchester Mining Corp. The name of the Company was changed to PNW Capital, Inc. on May 16, 2000. In 2002, PNW Capital, Inc. acquired Industrial Mine…
On September 9, 2014 the Company entered into a Share Exchange Agreement with CTT Pharmaceuticals, Inc. (“CTT Pharma”), and its then existing shareholders. As a result of this transaction, CTT Pharma became a wholly owned subsidiary of the Company. Our operations are conducted through CTT Pharma. On…
CTT Pharma specializes in drug delivery systems technology within the pharmaceutical industry. CTT Pharma’s focus is fast dissolving drug delivery systems. The company’s revolutionary technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or …
The Wafer is an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The wafer is formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer formulation relat…
The wafer is treated with a pharmaceutical agent designed to reduce or treat a medical condition.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice